Drug Profile
HORA RLBP1
Alternative Names: HORA-RLBP1Latest Information Update: 23 Jul 2021
Price :
$50
*
At a glance
- Originator INSERM; The Institute for Neurosciences of Montpellier
- Developer Coave Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Retinal dystrophies
- No development reported Fundus albipunctatus
Most Recent Events
- 21 Jul 2021 Horama is now called Coave Therapeutics
- 28 Aug 2019 No recent reports of development identified for preclinical development in Fundus-Albipunctatus in France (Ophthalmic, Infusion)
- 15 Feb 2019 Phase-I/II clinical trials in Retinal dystrophies (In adolescents, In adults, In children) in France (Ophthalmic) (EudraCT2017-002365-22)